RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• Activating mutations in RAC1 (Ras-related C3 botulinum toxin substrate 1) are found in approximately 7% of cutaneous melanoma cases.
• The RAC1^C85T mutation, leading to RAC1^P29S, results in a hyperactive GTPase implicated in melanoma cell signaling and tumor promotion.
• The exact mechanisms by which mutated RAC1 drives melanoma progression are not fully understood, particularly its downstream signaling pathways.

Purpose of the Study:

• To investigate whether the oncogenic signaling of mutated RAC1^P29S in melanoma is propagated through PI3Kβ (phosphoinositide 3-kinase beta).
• To assess the reliance of RAC1-mutated melanoma cells on PI3'-lipid signaling pathways for proliferation.
• To evaluate the therapeutic relevance of targeting the RAC1 → PAK1 (p21-activated kinase 1) signaling axis in RAC1-mutated melanoma.

Main Methods:

• Utilized genetic and isoform-selective pharmacological inhibitors to block PI3Kβ and other PI3K isoforms.
• Assessed the sensitivity of melanoma cell lines expressing RAC1^P29S to PI3K inhibitors.
• Examined the response of RAC1^P29S-expressing melanoma cells to pharmacological inhibition of the RAC1 → PAK1 pathway.

Main Results:

• Melanoma cells with RAC1^P29S mutations showed minimal sensitivity to PI3Kβ inhibitors.
• These cells displayed variable responses to pan-class 1 PI3K inhibitors, suggesting limited dependence on PI3'-lipid signaling.
• Sensitivity to RAC1 → PAK1 pathway inhibitors was also variable, questioning their clinical utility for RAC1-mutated melanoma.

Conclusions:

• Oncogenic RAC1^P29S signaling in melanoma does not appear to be primarily mediated by PI3Kβ.
• RAC1-mutated melanoma cells may not depend on PI3'-lipid signaling for proliferation.
• Targeting the RAC1 → PAK1 pathway may have limited efficacy in treating patients with RAC1-mutated melanoma.